Latest Asx Limited News

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

ASX Limited reaffirms its FY26 expense growth guidance while detailing progress on its five-year transformation and addressing regulatory challenges. Strong FY25 financial results and a robust market pipeline underpin the company’s outlook.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

ASX Limited has updated its dividend notification to include the New Zealand dollar exchange rate, NZD equivalent dividend amount, and the dividend reinvestment plan price for the first half of FY25.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

Gladiator Resources has inked a strategic agreement with Apex USA Resources to explore and develop rare earth element tenements in the United States, marking a significant diversification from its Tanzanian uranium projects.

ASX Limited reported a solid FY25 financial performance with a 7.5% rise in underlying net profit and a higher fully franked dividend, while advancing its CHESS replacement project amid ongoing regulatory scrutiny.

ASX Limited has announced a fully franked ordinary dividend of AUD 1.121 per share for the half-year ending June 2025, alongside a dividend reinvestment plan offering shareholders flexible currency choices.

ASX Limited reported a robust FY25 with revenue and underlying profit growth, while navigating regulatory scrutiny following a major settlement incident. The company advances its technology transformation and sustainability agenda as it seeks to rebuild trust and deliver shareholder value.

ASX has revealed it expects to incur an additional $25 million to $35 million in operating expenses in FY26 due to the ongoing ASIC compliance inquiry. Despite this, the company remains committed to its five-year strategy focused on technology and risk management.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

ASIC has initiated a comprehensive compliance inquiry into ASX’s governance, risk management, and operational capabilities, folding its previous CHESS incident probe into this broader review. ASX pledges full cooperation amid ongoing technology upgrades.